Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA clears IND application for NNI-362

May 8, 2019

FDA approves Ruzurgi for pediatric patients with Lambert-Eaton myasthenic syndrome

May 7, 2019

Phase III trial of Epidiolex in TSC meets primary endpoint

May 7, 2019

Axsome announces expedited development and pivotal status for AXS-05 for the treatment of MDD

May 7, 2019

Skyhawk and Takeda collaborate to develop small-molecule treatments for neurodegenerative diseases

May 7, 2019

Esteve Pharmaceuticals presents new analgesics

May 7, 2019

Huntington's hopefuls present at AAN 2019

May 7, 2019

Targeting metabolism prevents epilepsy after TBI

May 7, 2019

Small-molecule HDAC6 inhibitor improves memory and learning in fragile X syndrome in vivo

May 7, 2019

Myelin from hair stem cells

May 7, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.